Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06288451 · ClinicalTrials.gov registry record · Phase 2
DePTH: De-emphasize PTH
A Phase 2 study of Kidney Failure, Chronic and Chronic Kidney Disease Mineral and Bone Disorder, sponsored by University of Washington.
- Active
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT06288451: Active Phase 2 study of Kidney Failure, Chronic and Chronic Kidney Disease Mineral and Bone Disorder, sponsored by University of Washington.
NCT06288451 is a Phase 2 study of Kidney Failure, Chronic and Chronic Kidney Disease Mineral and Bone Disorder that is active but no longer recruiting, run by University of Washington. The registered enrollment target is 90 participants, below the 328-participant average among 23 other Kidney Failure, Chronic trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06288451, a Phase 2 study of Kidney Failure, Chronic and Chronic Kidney Disease Mineral and Bone Disorder, is active but no longer recruiting, sponsored by University of Washington.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
The De-emphasize Parathyroid Hormone (DePTH) Study is a 12-month pragmatic, randomized, parallel-group, active comparator, open-label, blinded end-point study of 90 patients with incident or prevalent secondary hyperparathyroidism and kidney failure treated with in-center hemodialysis. It tests the hypothesis that low fixed-dose oral calcitriol (intervention) will have more favorable effects on a comprehensive panel of biomarkers that assesses mineral metabolism, bone turnover, and serum calcification propensity, compared with variably-dosed intravenous activated vitamin D titrated to PTH targets (usual care).
Primary Outcome
Change in fibroblast growth factor-23
Conditions Studied
Interventions
- DRUG Oral calcitriol with cinacalcet rescue
- DRUG IV activated vitamin D
Study Locations (1)
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2024-03-11 |
| Est. Completion | 2027-02-28 |
| Phase | Phase 2 |
What the registry record for NCT06288451 still lists
NCT06288451 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 328-participant average among 23 other Kidney Failure, Chronic trials with a reported enrollment target (73% lower).
The record links to 2 conditions, with Kidney Failure, Chronic appearing as the primary indexed condition, and to 2 interventions - of which Oral calcitriol with cinacalcet rescue is the first listed.
NCT06288451 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT06288451 about?
NCT06288451 is a clinical study titled "DePTH: De-emphasize PTH". The De-emphasize Parathyroid Hormone (DePTH) Study is a 12-month pragmatic, randomized, parallel-group, active comparator, open-label, blinded end-point study of 90 patients with incident or prevalent secondary hyperparathyroidism and kidney failure treated with in-center hemodialysis. It tests the ...
What is the current status of trial NCT06288451?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2024-03-11. Estimated completion is 2027-02-28.
What conditions does trial NCT06288451 study?
This clinical trial studies the following conditions: Kidney Failure, Chronic, Chronic Kidney Disease Mineral and Bone Disorder.
What interventions are being tested in trial NCT06288451?
The interventions under investigation include: Oral calcitriol with cinacalcet rescue (DRUG), IV activated vitamin D (DRUG).
Who is sponsoring clinical trial NCT06288451?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06288451 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Failure, Chronic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06288451's enrollment target sits among peer trials
90 9th of 23 higher than 15 of 23 other Kidney Failure, Chronic trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Failure, Chronic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase II Study to Evaluate the Efficacy of IdeS to Desensitize Transplant Patients With a Positive Crossmatch Test
COMPLETED · Phase 2
-
Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)
COMPLETED · Phase 2
-
Exercise Intolerance in Renal Failure
COMPLETED · Phase 2
-
International (Pediatric) Peritoneal Biobank
RECRUITING
-
Empagliflozin in ESKD - A Feasibility Study
RECRUITING · Phase 1
-
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI